相关实验视频
Updated: Jun 17, 2025
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
10.6K
使用深度学习发现潜在的抗糖尿病.
Jianda Yue1, Jiawei Xu1, Tingting Li1
1The National and Local Joint Engineering Laboratory of Animal Peptide Drug Development, College of Life Sciences, Hunan Normal University, Changsha, 410081, China; Peptide and Small Molecule Drug R&D Plateform, Furong Laboratory, Hunan Normal University, Changsha, 410081, Hunan, China; Institute of Interdisciplinary Studies, Hunan Normal University, Changsha, 410081, China.
Computers in biology and medicine
|August 13, 2024
概括
这项研究引入了先进的深度学习模型来预测抗糖尿病 (ADP),显著提高了发现效率. 开发的CNN模型实现了90.48%的准确性,有助于识别糖尿病的新治疗方法.
科学领域:
- 生物化学和生物信息学
- 计算机化药物发现.
- 酸科学是一种科学.
背景情况:
- 抗糖尿病 (ADP) 对于糖尿病管理至关重要,但其发现受到数据限制和实验成本的阻碍.
- 识别ADP的传统方法耗时且昂贵,需要先进的计算方法.
研究的目的:
- 开发和评估深度学习模型,以准确有效地预测抗糖尿病.
- 通过利用先进的计算技术来解决ADP发现的挑战.
- 探索新型ADP的产生和选,以寻找治疗潜力.
主要方法:
- 开发两种深度学习模型:一个单通道CNN和一个CNN+RNN+Bi-LSTM网络.
- 使用进化规模模型 (ESM-2) 和10倍交叉验证进行数据预处理,用于模型培训和评估.
- 使用SeqGAN生成新的候选ADP,并使用CNN模型进行选,随后进行物理化学和结构性质评估.
主要成果:
- 单通道CNN模型表现出卓越的性能,在一个独立的新识别的ADP测试组中达到90.48%的准确性.
- 开发的模型超越了用于抗糖尿病预测的现有工具.
- 该研究成功选了具有有利物理化学和结构性质的潜在ADP,用于制药应用.
结论:
- 该研究建立了强大的深度学习模型来预测抗糖尿病,显著地推进了该领域.
- 开发的模型可以有效地应用于发现和选用于抗糖尿病疗法的新候选者.
- 这项研究解决了在基于的抗糖尿病药物发现中对有效方法的关键需求.
相关概念视频
01:24Glucagon-like Receptor Agonists
308
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
308
01:23Dipeptidyl Peptidase 4 Inhibitors
179
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179